Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shashank Desai

Advanced Heart Failure and Transplant Cardiology Falls Church, VA Medical Doctor

NPI 1134156151 CMS profile 187221

3300 Gallows Rd, Physician Billing, Falls Church, VA 22042

Open in the dashboard

General payments

$80,081

205 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$118,598 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Shashank Desai of Falls Church, VA is reported in the CMS Open Payments database as having received $80,081 across 205 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $118,598 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,142 28
2024 General $8,700 30
2023 General $13,536 27
2022 General $17,781 45
2021 General $15,743 34
2020 General $4,557 9
2019 General $14,623 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shashank Desai
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Shashank Desai were reported at $5,142. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Shashank Desai Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $14,623 $863 $224–$4,562 $163
2020 $4,557 $452 $122–$3,992 $114
2021 $15,743 $550 $159–$3,571 $132
2022 $17,781 $729 $221–$4,357 $149
2023 $13,536 $1,002 $309–$5,827 $160
2024 $8,700 $931 $273–$5,204 $164
2025 $5,142 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $65,675 138 payments
  2. Medtronic Vascular, Inc. $4,647 3 payments
  3. Abiomed $4,101 35 payments
  4. TransMedics, Inc. $3,084 3 payments
  5. CVRx, Inc. $1,032 7 payments
  6. Impulse Dynamics (USA) Inc. $365 3 payments
  7. Paragonix Technologies, Inc. $337 1 payment
  8. Edwards Lifesciences Corporation $300 2 payments
  9. AstraZeneca Pharmaceuticals LP $117 1 payment
  10. Actelion Pharmaceuticals US, Inc. $113 2 payments
  11. Other $308 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $25,113 15 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,019 9 payments
  3. Travel and Lodging $14,885 47 payments
  4. Food and Beverage $9,763 120 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $9,102 10 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $4,200 4 payments
Products named General payments · program years 2019–2025
  1. HeartMate 3 Left Ventricular Assist Device $9,652 10 payments
  2. MITRACLIP Structural Heart $8,189 17 payments
  3. CARDIOMEMS $8,136 14 payments
  4. MITRACLIP Vascular $8,106 8 payments
  5. CardioMEMS HF System $6,328 7 payments
  6. HeartMate Touch $5,421 18 payments
  7. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $4,883 24 payments
  8. HeartMate 3 Left Ventricular Dev $4,422 8 payments
  9. 2ND GEN CENTRIMAG PRIMARY CONSOLE $4,200 5 payments
  10. ORGAN CARE SYSTEM $3,084 3 payments
  11. Other $12,497 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

196

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$120,765

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

44.9%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 40 $69,092
Farxiga Dapagliflozin Propanediol Brand 17 $24,111
Jardiance Empagliflozin Brand 19 $14,944
Eliquis Apixaban Brand 12 $11,120
Spironolactone Generic 47 $571
Ezetimibe Generic 11 $414
Metoprolol Succinate Generic 24 $351
Carvedilol Generic 26 $162

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$19,924

Medicare's payments for the services billed

Medicare patients

83

Average age 70

Services billed

201

19 women, 64 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 71%
Chronic kidney disease 71%
Diabetes 66%
Atrial fibrillation 52%
Arthritis 42%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $28
$28 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $26
$26 40 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record